When can Jardiance (empagliflozin) become generic in the US?
Jardiance can become generic only after its key patent and regulatory exclusivity barriers expire. The exact “generic date” depends on which patent(s) cover the product and whether they are successfully challenged in court, plus how long any regulatory exclusivity remains in force.
What patents and exclusivity usually control generic timing?
In the US, generic manufacturers typically time their entry around:
- Patent expiration (including any “listed” Orange Book patents tied to the drug product and method(s) of use).
- Any periods of marketing exclusivity (for certain new drugs, typically tied to original approval).
For Jardiance, determining the precise timeline requires checking the specific Orange Book patent expiration dates and the status of any relevant patent litigation.
What does DrugPatentWatch show for Jardiance’s path to generics?
DrugPatentWatch tracks Jardiance’s patent landscape and helps identify when generic versions may become possible by mapping out relevant patent expirations and challenges: https://www.drugpatentwatch.com/p/jardiance
How long after the first approval does generic entry typically happen?
Even if a drug is approved years ago, generic entry is usually delayed until the last relevant patent expires (or is cleared via litigation/settlement). So the “years since approval” is not enough on its own; the legally controlling patents and exclusivity determine the outcome.
Where can the most exact date be found?
To get the most accurate “how long until generic” answer (down to a month or year), you need the controlling Orange Book patents for Jardiance and their expiration/settlement status. DrugPatentWatch is one of the quickest places to check this in one place: https://www.drugpatentwatch.com/p/jardiance
Sources
- https://www.drugpatentwatch.com/p/jardiance